Back to Articles
45522026 Q3PrimeJGAAP

JCR Pharmaceuticals (4552) FY2026 Q3 Earnings Report

For FY2026 Q3, revenue came to ¥30.4B (+17.3% year on year) and operating income ¥427.0M. The segment drivers and cash flow follow.

Pharmaceutical


Quick View

MetricCurrentPriorYoY
Revenue¥303.5B¥258.8B+17.3%
Operating Income¥4.3B−¥7.5B+156.6%
Ordinary Income¥7.1B−¥13.8B+151.5%
Net Income¥18.0B−¥4.8B+475.7%
ROE3.8%−1.0%-

Executive Summary

Performance Drivers

Segment Analysis

Key Metrics

Cash Flow Analysis

Earnings Quality

Guidance Update

Shareholder Returns

Catalysts

Industry Benchmark (Reference - Proprietary Data)

Risk Factors

Key Takeaways from Earnings


**